SCHEDULE: Anson Funds Discloses 4.9% Stake in Hepion Pharma

Anson Funds Management LP and related entities reported a 4.9% beneficial ownership stake in Hepion Pharmaceuticals, Inc., including shares from warrants.

Summary

• Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo, and Mr. Moez Kassam collectively reported beneficial ownership of 576,482 shares of Hepion Pharmaceuticals, Inc. Common Stock.
• This aggregate amount represents 4.9% of the outstanding Common Stock of Hepion Pharmaceuticals, Inc.
• The reported ownership includes shares of Common Stock underlying outstanding warrants held by the reporting persons.
• The warrants include a beneficial ownership limitation, preventing exercise if it would result in beneficial ownership exceeding 4.99% of the outstanding Common Stock.
• The percentage of class is calculated based on 10,976,276 shares of Common Stock issued and outstanding as of May 19, 2025, plus the 576,482 shares receivable upon warrant exercise, totaling 11,552,758 shares.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership, which is neutral in sentiment. While a significant stake can be seen positively, the filing itself does not contain positive or negative operational news.

Positives

• The disclosure of a significant stake by institutional investors like Anson Funds can signal confidence in the company's long-term prospects to other market participants.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Industry Context

This filing is a Schedule 13G, an SEC form used by passive investors to report beneficial ownership of 5% or more of a company's stock. As an amendment, it updates a previously filed statement. For Hepion Pharmaceuticals, a biotechnology company, the disclosure of a significant stake by an investment firm like Anson Funds indicates a notable investor's position in the company, which can be interpreted by the market as a vote of confidence or a strategic investment.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding significant ownership stakes, which can influence investor perception and potentially trading activity.

Key Dates

Keywords

Hepion Pharmaceuticals, Anson Funds, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Investment Management, Biotechnology